Associated Papers
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
38564707 (PubMed )
Supplement: cd-23-1217_supplementary_table_5_suppst5.xlsx › table_uff
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid AB et al.
Cancers, 2020
The prognostic effects of somatic mutations in ER-positive breast cancer.
Griffith OL et al.
Nature Communications, 2018
Gastrointestinal malignancies harbor actionable MET exon 14 deletions.
Lee J et al.
Oncotarget, 2015
26375439 (PubMed )
Supplement: oncotarget-06-28211-s003.xlsx › Cosmic_MET
Emerging importance of ALK in neuroblastoma.
Azarova AM et al.
Seminars in Cancer Biology, 2011
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
21575214 (PubMed )
Supplement: 1476-4598-10-54-S3.XLS › mutations.txt
Identification of ALK as a major familial neuroblastoma predisposition gene.
Mossé YP et al.
Nature, 2008
Select a paper to view details